TG Therapeutics posts Q1 profit and nearly doubles revenue, driven by rising Briumvi sales and higher full-year guidance for 2025.

A group of students at Keith Gill’s old high school have been finding purpose and success in learning about stock trading.

As market uncertainty rises, the historically defensive consumer staples sector is drawing renewed attention, potentially signaling a broader move towards recession-resistant portfolio strategies.

While analysts may be cautious about Expedia's Q1 earnings disclosure next week, the smart money seems bullish on EXPE stock.